CD47 and cancer: Interestingly, coating oncolytic herpes simplex virus with CD47 or on the opposite, targeting CD47 using antibodies encoded within oncolytic viruses has both been successfully developed as approaches to improve the antitumor innate immune responses to cancer [30,31].